VITALIST
BAY

Adeel Khan is a Canadian Board Certified Physician and a leading figure in regenerative medicine and longevity. As the founder of Eterna Health Clinics, he is recognized for his innovative work in stem cell therapy and anti-aging treatments. Dr. Khan has gained global recognition for treating high-profile clients, including celebrities and elite athletes. His dedication to advancing regenerative medicine and improving health outcomes has made him a respected name in the field.

Siim Land is an 8-time bestselling author, anthropologist, keynote speaker, and longevity advocate dedicated to maximizing healthy human lifespan. With over a decade of research into health, fitness, and mindset, he empowers high-performing individuals through his YouTube channel, blog, and online coaching. Combining a background in Cultural and Social Anthropology with a passion for human optimization, Siim Land delivers transformative insights into body-mind empowerment. His Amazon-bestselling books and rising video courses inspire audiences worldwide to thrive physically, mentally, and professionally.

Mac Davis is the founder of Minicircle, a pioneering company focused on revolutionizing gene therapy. With a mission to enhance human health and sovereignty, he developed a reversible human genetic enhancement protocol that uses non-inflammatory, non-heritable plasmids to safely introduce genes into the body without altering the genome. Mac’s innovative approach challenges traditional medical practices, offering a fast, accessible, and ethical alternative to lifelong treatments. His work aims to empower individuals and communities, ensuring that gene therapy is available to all, free from the constraints of the current healthcare system.

Joseph Everett, also known as WIL, is the creator of the popular YouTube channel "What I've Learned." His content focuses on connecting the dots, making conclusions, and weighing them against modern dogma. Joseph covers a wide range of topics, including health, productivity, cognitive enhancement, and general self-improvement. His goal is to provide viewers with actionable takeaways that can be applied to daily life. Joseph's work is appreciated for its insightful and evidence-based approach to complex subjects.

Irina Conboy, PhD, is a Professor of Bioengineering at the University of California, Berkeley, where she leads groundbreaking research on aging and rejuvenation. As the head of the Conboy Laboratory, her work has advanced understanding of how aging impacts stem cells and tissues. Notable for her innovative use of heterochronic parabiosis and blood apheresis, Dr. Conboy aims to develop therapies that reverse age-related decline, promoting healthier aging and tissue regeneration to extend lifespan and improve quality of life in older adults.

Farbood Nivi is an accomplished entrepreneur and product leader, best known for founding Grockit, an online collaborative learning platform powered by machine learning, which was later acquired by Kaplan. He has also co-founded Coinmine, a company focused on making cryptocurrency mining accessible to everyone. With a background in psychology from the University of Michigan, Farbood continues to drive innovation in the tech and education sectors, leveraging his extensive experience to create impactful and user-friendly solutions.

Leo Nissola, MD, is a distinguished immunologist, researcher, and cancer specialist. He serves as the Chief Scientific Officer at FirstBio Research, focusing on drug development and medical intelligence. Dr. Nissola previously worked as a Medical Oncology fellow at MD Anderson Cancer Center, supporting prostate cancer clinical trials. During the COVID-19 pandemic, he advised health officials and contributed epidemiological models used by the White House. A bestselling author of THE IMMUNITY SOLUTION, his innovative work in oncology and immunotherapy has earned international recognition, including collaborations with Nobel Laureates and industry leaders.

Jacob Peters is the Founder of Superpower.com, an audacious venture dedicated to transforming health and longevity. A serial entrepreneur, he co-founded Launch House, a dynamic startup ecosystem investing $25k-$250k in early-stage companies, and Commsor, a pioneering platform for community teams that raised $68M. Formerly a Data Scientist at J.P. Morgan, Jacob spearheaded innovation, winning accolades from CEO Jamie Dimon and presenting to 6,000+ attendees at a global symposium. Passionate about bold ideas, Jacob thrives at the intersection of technology, community, and human potential.

Laila Zemrani is an entrepreneur with extensive experience in personalized wellness and health data analytics. She is the co-founder and CEO of Fitnescity, a company that offers lab-based assessments to help individuals improve their fitness, nutrition, and overall health. Fitnescity partners with leading labs, hospitals, and clinics nationwide to provide accessible wellness testing. An early adopter and advocate of personalized wellness and self-collected data, her work focuses on empowering individuals to take control of their health through accessible and understandable data.

Adam Bataineh is a medical doctor and the founder of Numenor, an online longevity clinic based in London. He is dedicated to making cutting-edge health interventions accessible to everyone, with a focus on personalized, preventative healthcare. Adam's work at Numenor aims to extend healthspan by targeting key biomarkers associated with aging-related diseases and providing comprehensive health assessments and personalized treatment plans. His belief in the urgent need to address aging drives his mission to bring longevity medicine to a wider audience.

David Barzilai is a physician, longevity consultant, and health coach, known for his expertise in geroscience and longevity medicine. As the founder and CEO of Healthspan Coaching LLC, he provides personalized health and longevity coaching, integrating the latest scientific research and technology. David is also an active member of the longevity community, engaging with scholars and practitioners on social media under the handle @agingdoc1. His work focuses on promoting healthy aging and optimizing healthspan through evidence-based practices and lifestyle interventions.

Christine Peterson is a visionary leader and advocate for emerging technologies, best known for co-founding the Foresight Institute, which focuses on nanotechnology and its long-term impacts. She is credited with coining the term "open source software," highlighting her influence on both technology and intellectual property. Christine is also an author and lecturer, sharing her insights on nanotechnology, AI, and longevity to educate the public and policymakers about the potential of these transformative fields.

Parmita Mishra is a computational biologist and entrepreneur, known for founding Precigenetics, a company focused on developing advanced non-invasive diagnostic tools that integrate biophotonics with machine learning. She is dedicated to pushing the boundaries of healthcare technology, particularly in the field of non-invasive cancer diagnostics. Parmita's work aims to enhance the identification of molecular signatures unique to cancerous cells, leveraging machine learning algorithms to improve detection and classification.

Kenneth Scott is an 81-year-old biohacker and longevity enthusiast with a biological age of 18. He has a diverse background, including roles as a mathematician, economist, and aeronautical engineer in the Royal Canadian Air Force. Kenneth is also a biotech investor and real estate developer. He and his wife spend significant resources on experimental treatments to reverse aging and have invested in biotech companies focused on longevity. Kenneth is a prominent figure in the longevity community, advocating for the potential of extended human lifespan and immortality.

Ari Tulla is a San Francisco-based entrepreneur and the co-founder and CEO of Elo Health, a precision nutrition service transforming food from the cause of disease to medicine. With a background as CEO of Quest Analytics and co-founder of BetterDoctor, Ari has a proven track record of leading companies through pivotal growth stages. He is also an active angel investor with a portfolio of over 50 startups, including Virta Health and Oura. Outside of work, Ari enjoys rock climbing, surfing, and spending time with his family.

Akshay Sanghavi is the founder of Yuvan Research, a company focused on reversing biological age to cure chronic diseases. With over a decade of experience in epigenetics and gene regulation, Akshay has pioneered non-chemotherapy, immune-based cancer therapies and researched natural solutions to ameliorate aging-related biochemical declines. He also led innovative advancements in LED lighting technology as COO, where his team developed disruptive solutions that reduced parts by 70% and introduced the industry’s first lifetime warranty. Akshay’s work continues to push the boundaries of health and technology innovation.

Kazuma Kishida is the pioneering CEO of Dioseve, a groundbreaking biotech company revolutionizing infertility treatment by developing human eggs from iPS and ES cells. Under his leadership, Dioseve is at the forefront of creating new possibilities for couples struggling with infertility, aiming to redefine reproductive medicine. With a strong foundation in financial strategy from his tenure as a financial analyst at Houlihan Lokey, Kaz combines scientific innovation with business acumen to drive transformative advancements in biotech. Based in Tokyo, he is committed to delivering hope through science and innovation.

Paul Kiesow brings 35+ years of engagement in the field of anti-aging and vibrant life extension to Vitalist Bay 2025. With his emphasis on the critical role of brain preservation and health, Paul shares insights from his journey, his inspirations, strategies and successes. His work as an early member and writing contributor with the Life Extension Foundation in the 1980s and '90s led to an impactful personal plan regarding metabolic optimization, neuron protection, and whole brain health—now evidenced by recent medically evaluated cranial CT scans showing no signs of age-related decline. At 72, Paul continues to defy aging norms and is positively energized by the expectation of a vibrant extended life.

Dr. Orion Taraban is a licensed psychologist with over a decade of experience in clinical practice. He is the creator and host of PsycHacks, a popular platform that offers brief, thought-provoking episodes several times a week on a variety of psychological topics inspired by his clinical work. PsycHacks has garnered significant attention, with over one hundred million views on YouTube, establishing Dr. Taraban as a thought leader in popular psychology. Dr. Taraban's professional focus centers on relationships and personal development. Through his work, he has assisted thousands of individuals in achieving their personal growth and relationship goals. His mission is to reduce unnecessary suffering by inspiring listeners and viewers to see themselves and their world in a new light.

Chris Mirabile is the Founder and CEO of NOVOS, a pioneering consumer longevity biotech company dedicated to addressing the mechanisms of aging. Overcoming a brain tumor at a young age, Chris has devoted his life to health and longevity, achieving a biological age significantly younger than his chronological age through a balanced lifestyle and innovative health practices. He has been featured in numerous publications and has spoken at various conferences about his journey and the science behind slowing aging. Chris is passionate about making longevity achievable and accessible for all through scientifically validated, over-the-counter formulations and best-in-class biological age tests.

Clara Fernandez Porta is a visionary leader and innovator in the field of longevity, known for her roles as the CEO and co-founder of RxLongevity and the founder of Europe's largest Longevity Clinic for Seniors. She has been recognized as one of the Top 100 Female Leaders and Top 100 Forbes Creatives in Spain, and is also a celebrated author with Penguin Editorial, contributing significantly to the discourse on healthy aging and longevity. Her work focuses on empowering seniors to live longer, healthier lives through personalized health plans and cutting-edge technology.

Virginia Gambardella is the founder of Anapana and co-host of the Tressessanta podcast, ranked among Italy's top 100. She is passionate about building communities around mental and physical well-being, having grown a community of 300K across social media platforms. With a background in strategy and operations, Virginia has worked at McKinsey & Company and Serenis, where she led operations. Her entrepreneurial journey includes founding Moebius Milano and buoono.farm. A Bocconi graduate, she brings a unique mix of academic excellence and hands-on experience in diverse sectors.

Chase Denecke is an entrepreneur and scientist with extensive experience in computational biology and biotechnology. He is the founder and Chief Executive Officer of Bootstrap Bio, a company specializing in advanced biotechnological research and development. Through his leadership at Bootstrap Bio, Mr. Denecke aims to advance the development of innovative biotechnological solutions, leveraging his expertise to address complex challenges in the field.

Dr. Molly Maloof is a physician, entrepreneur, and educator with over a decade of experience in health optimization and personalized medicine. She is the founder and CEO of Adamo Bioscience, a company pioneering the science of love and human connection to enhance health and longevity. Through her leadership at Adamo Bioscience, Dr. Maloof is developing biological, psychological, psychedelic, and technological solutions to foster love and connection, aiming to create a healthier, happier, and more resilient world.

Goktug Yilmaz is an entrepreneur and software developer passionate about creating engaging digital experiences. He is the founder of Colonist.io, a popular online board game platform that brings strategy enthusiasts together from around the world. With a background in computer science and a deep interest in game design, Goktug has dedicated his career to building intuitive and scalable software. Drawing on his experience in designing user-centered applications, he is interested in how digital tools can enhance health tracking, improve stress management, and optimize performance. His work focuses on enhancing user experience and fostering online communities through innovative and accessible gameplay.

​Kian Sadeghi is an entrepreneur with a background in computational biology. He is the founder and CEO of Nucleus, a consumer health platform leveraging whole-genome sequencing to provide comprehensive genetic health insights. Kian's vision is to empower individuals with personalized health information to mitigate disease risks and promote well-being. Under his leadership, Nucleus has secured significant funding from prominent investors, including Alexis Ohanian's Seven Seven Six and Peter Thiel's Founders Fund. The platform integrates genetic data with lifestyle factors to deliver actionable health insights, aiming to revolutionize preventive healthcare.

​Dr. Anna Vakhrusheva is a bioengineer and entrepreneur specializing in anti-aging therapies, immunology, and drug development. She currently serves as the Chief Technology Officer (CTO) at Unlimited Bio, where she leads the development of gene therapies aimed at promoting healthy longevity. Her career includes significant roles such as CEO of Betuvax, a company focused on vaccine development from research and development to clinical trials, and lead bioengineer at Longaevus Technologies, where she explored her interests in anti-aging therapies and drug development. Through her leadership at Unlimited Bio, Dr. Vakhrusheva continues to contribute to advancements in biotechnology, focusing on interventions that promote healthy longevity and improve quality of life.

​Ivan Morgunov is an entrepreneur and advocate for longevity science, with a focus on developing genetic therapies aimed at combating aging. He is the CEO and co-founder of Unlimited Bio, a company dedicated to creating rejuvenation treatments through advanced gene therapy techniques. Ivan's journey into the longevity field began over seven years ago, driven by a personal commitment to exploring diverse pathways to healthy aging and extending human lifespan. Prior to founding Unlimited Bio, he established Longaevus Technologies, a venture studio focused on longevity research, where he led efforts to discover innovative approaches to reducing chronic diseases associated with aging. With over five years of experience in leading successful projects and startups, Ivan has demonstrated a strong ability to drive scientific initiatives from concept to implementation. His leadership at Unlimited Bio reflects his dedication to translating cutting-edge scientific research into practical solutions for aging, aiming to make significant strides in the field of life extension. Through his work, Ivan Morgunov continues to contribute to the advancement of biotechnology, focusing on interventions that promote healthy longevity and improve quality of life.

Dr. Koji Tanabe is a pioneering expert in induced pluripotent stem cells (iPSCs) with a strong track record in both research and business. He was a key contributor and co-author of the groundbreaking study that led to the world’s first successful establishment of human iPSCs, a discovery that earned the Nobel Prize. Under his leadership, I Peace has pioneered scalable, high-quality iPSC manufacturing and is at the forefront of developing iPSC-based applications for rejuvenation. His contributions to the industry earned him recognition as one of World Biz Magazine’s “Top 100 Innovation CEOs” in 2021.

Dr. Drew Taylor is an entrepreneur and regenerative medicine pioneer with a diverse background in molecular biology, biomedical engineering, and professional athletics. He is the co-founder and Chief Executive Officer of Acorn Biolabs, a Toronto-based healthcare technology company specializing in non-invasive, follicle-based live cell collection and preservation for personalized regenerative medicine. Prior to founding Acorn Biolabs in 2017, Dr. Taylor served as Chief Science Officer at Epic Capital Management, where he engaged with the burgeoning biotech startup community. He also contributed to the Bioengineering of Skeletal Tissues Team at Mount Sinai Hospital, focusing on cartilage regeneration research. Through his leadership at Acorn Biolabs, Dr. Taylor is committed to making regenerative medicine accessible and personalized, enabling individuals to preserve their cells for future therapeutic use.

Aykut Karaalioglu is an accomplished entrepreneur and investor, best known for founding MobileAction, a company specializing in app discovery and optimization. He has held various leadership roles, including CEO of SearchAds.comand Growth Lead at ScoreBeyond. Aykut is also an active angel investor and advisor to several startups, leveraging his extensive experience in product management and user acquisition to drive innovation and growth in the tech industry.

Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.

Caitlin Lewis is the Director of Project Pipeline and Strategy at the LEV Foundation, where she plays a crucial role in evaluating progress and identifying therapeutic targets in the field of longevity. Introduced to the longevity field in 2017 through the SENS Research Foundation's MitoSENS project, Caitlin has been instrumental in developing strategies for nascent projects and facilitating their advancement. Her work focuses on promoting research to prevent and reverse age-related diseases, aiming to improve human healthspan.

Peter Fedichev is an entrepreneur and scientist with over 20 years of experience in academic research and biotech business. He is the founder of Gero, a longevity startup focused on developing therapies to extend a healthy human lifespan. Peter's scientific background lies in condensed matter physics, biophysics, and bioinformatics. His work aims to uncover the principles of aging and develop interventions to promote healthy longevity.

Matthew "Oki" O'Connor is the Co-CEO of Cyclarity Therapeutics, a company focused on developing treatments for cardiovascular diseases through innovative cyclodextrin technology. With a Ph.D. in Biochemistry and extensive research experience in aging and regenerative medicine, O'Connor has made significant contributions to the field. His work aims to eliminate toxic oxidized cholesterol, a major factor in atherosclerosis, and improve overall healthspan.

Marco Quarta is a distinguished scientist and entrepreneur, currently serving as the Co-founder, President & CSO of Rubedo Life Sciences. He holds a Ph.D. in Neuroscience from the University of Padua and has conducted post-doctoral research in aging and stem cell biology at Stanford University. Marco has over 20 years of experience in the fields of aging, stem cells, and regenerative medicine, and has co-founded several biotech companies. His work focuses on developing treatments for age-related diseases and extending healthspan by targeting pathological cells involved in the aging process.

Mahdi Moqri, Ph.D., is a Harvard Faculty member, computational biologist, and the founding director of the Biomarkers of Aging Consortium. His interdisciplinary expertise spans omics, bioinformatics, and computational methods to explore the molecular mechanisms of aging and develop innovative therapies for age-related diseases. As director, he leads international collaborations to validate blood-based biomarkers of aging, with research published in Cell and Nature Medicine. Previously, Dr. Moqri completed a postdoctoral fellowship at Stanford University and has raised over $1M to advance aging research. He is passionate about enhancing human health and longevity.

Reason is the co-founder and CEO of Repair Biotechnologies, pioneering solutions to combat aging and extend human healthspan. An active angel investor in the longevity sector, he has backed companies like Oisin Biotechnologies and Leucadia Therapeutics. As a passionate patient advocate, Reason supports fundraising and outreach efforts for organizations like the Methuselah Foundation and SENS Research Foundation. He is also the founder and writer of Fight Aging!, a prominent biotechnology news and commentary platform. Before his biotechnology career, Reason was a consultant in the software industry.

Vera Gorbunova is a distinguished biologist and the Doris Johns Cherry Professor at the University of Rochester, where she also co-directs the Rochester Aging Research Center. She earned her B.Sc. from Saint Petersburg State University and her Ph.D. from the Weizmann Institute of Science. Gorbunova's pioneering research focuses on the mechanisms of aging and cancer resistance, particularly in long-lived mammals like the naked mole rat. Her work has identified high molecular weight hyaluronan as a key mediator of cancer resistance, earning her recognition and numerous awards in the field of aging research.

Martin Borch Jensen is the co-founder and CSO of Gordian Biotechnology, focused on developing pooled in vivo therapeutic screenings to address aging-related diseases. He has a rich background in aging biology, mitochondrial health, and neurodegenerative diseases, with key publications in Cell Metab and Nature. Jensen holds a prestigious NIH K99/R00 award and previously studied DNA repair mechanisms in aging at the National Institute on Aging. In addition to his leadership role at Gordian, he serves on multiple scientific advisory boards and co-authored a popular science book on intermittent fasting and aging.

Mike Conboy, PhD, is a leading Research Scientist at the University of California, Berkeley, specializing in aging and rejuvenation research. As a key member of the Conboy Laboratory, he collaborates with his wife, Irina, to explore how aging affects stem cells and tissues. His work on heterochronic parabiosis and blood apheresis has shed light on potential therapies to reverse age-related damage and enhance tissue repair. Dr. Conboy is dedicated to advancing methods that could significantly improve healthspan and extend the healthy human lifespan.

Yuri Deigin is an entrepreneur, scientist, and biotech innovator with a deep focus on life sciences and longevity research. He is the co-founder and CEO of YouthBio Therapeutics, a company dedicated to developing cutting-edge gene therapies aimed at reversing aging processes at the cellular level. With a background in biotechnology, drug development, and artificial intelligence, Yuri has been at the forefront of translating scientific discoveries into practical solutions to combat age-related decline. His work is driven by a passion for advancing rejuvenation technologies to extend healthy human lifespan and improve quality of life.

Eleanor Sheekey is a dynamic scientist and communicator, blending cutting-edge research with engaging education. As a Postdoctoral Researcher at RIKEN, she explores skin aging and extracellular matrices, building on her PhD at the Cancer Research UK Cambridge Institute, where she studied p53 and cellular senescence. Creator of the Sheekey Science Show YouTube channel, Eleanor simplifies complex science for almost 50K subscribers, covering topics like longevity and CRISPR. She’s also a guest lecturer and director of Sheekey Science Solutions. Passionate about knowledge-sharing, Eleanor’s work inspires curiosity and advances understanding in biomedicine.

Dr. Keshav K. Singh, a globally recognized expert in longevity and mitochondrial science, is the founder and Chief Scientific Officer of Yuva Biosciences, a trailblazing biotech company focused on extending healthspan through mitochondrial innovation. As the Joy and Bill Harbert Endowed Chair at UAB and founding editor of Mitochondrion, Dr. Singh has authored over 100 publications and three books, earning honors like Stanford’s Top 2% Scientists and Newsweek’s Innovation Hero. A dynamic thought leader, he pioneers transformative research at the intersection of aging, health disparities, and mitochondrial genetics.

Kevin Perrott is an entrepreneur and scientist with over 15 years of experience at the intersection of biotechnology and longevity research. He is the founder and CEO of OpenCures, an organization dedicated to empowering individuals to harness the potential of self-directed health data and cutting-edge scientific insights to improve their longevity. Kevin’s background spans molecular biology, biogerontology, and bioinformatics. His work focuses on advancing personalized approaches to health optimization and developing therapies to combat the root causes of aging.

Alan Tomusiak is a researcher specializing in the biology of aging, with a focus on epigenetics and immunology. For his PhD, he studied in the Verdin Lab at the Buck Institute for Research on Aging. His research focuses on developing novel epigenetic clocks that are resistant to changes in immune cell composition, aiming to improve the accuracy of biological age predictions. Alan has also explored the effects of senolytic compounds on DNA methylation clocks, contributing to the understanding of how these interventions may influence biological aging. Through his work, Alan aims to uncover the molecular mechanisms underlying aging and develop interventions to promote healthy longevity.

​Dr. Andrea Cipriano is an esteemed scientist and educator with a profound dedication to unraveling the complexities of cellular biology and aging. He serves as an Instructor at Stanford University's Stem Cell Institute and the Department of Obstetrics and Gynecology, where his research centers on the roles of long non-coding RNAs in cell differentiation and the impact of chromatin structure on aging and its potential reversal. His Ph.D. work focused on the pivotal role of long non-coding RNAs in cell differentiation, a topic that continues to underpin his current research endeavors. In addition to his research, Dr. Cipriano is deeply committed to education. His passion for teaching stems from a belief in the transformative power of knowledge. Beyond his roles at Stanford, Dr. Cipriano contributes to the broader scientific community as a member of the Executive Committee of the Biomarkers of Aging Consortium, where he collaborates with leading experts to develop and validate biomarkers critical for assessing aging and longevity interventions. Through his multifaceted work, Dr. Cipriano aims to advance our understanding of aging processes and foster the development of interventions that promote healthy longevity

Vincent Weisser is a dedicated advocate for decentralized science and AI, known for his work on projects like VitaDAO, which funds longevity research, and Molecule, a platform for scientific funding. He is passionate about democratizing access to cutting-edge technologies and scientific progress, aiming to create a future where advanced AI and biotechnology are accessible to all. Vincent's diverse interests and contributions span across AI, biotechnology, energy, and more, making him a key figure in the tech and science communities.

Kai Micah Mills is the CEO of Cryopets, a startup specializing in cryopreservation for pets, and a co-founder of CryoDAO, a decentralized organization funding cryonics research. With a background as a tech entrepreneur and Thiel Fellow, Kai is dedicated to advancing cryopreservation technologies and making significant contributions to the field of life extension.

Laura Minquini is a longevity and women's health entrepreneur, known for her work in branding and luxury design. She has collaborated with prestigious companies such as Louis Vuitton, Apple, and Amazon. Laura is the founder of MYKIGAI, a discovery and recommendation platform for longevity, and the core lead of AthenaDAO, a decentralized collective funding women's health research. Her mission is to leverage her expertise to make science work for women, promoting healthier aging and well-being.

Patri Friedman is a prominent libertarian and anarcho-capitalist, known for founding The Seasteading Institute, which explores the creation of sovereign ocean colonies. He is also the General Partner at Pronomos Capital, a venture capital firm focused on developing experimental cities in developing countries. Patri's innovative approaches to governance and urban development continue to inspire discussions on alternative political and social systems.

Mark Lutter is the Founder and Executive Chairman of the Charter Cities Institute, a nonprofit organization dedicated to building the ecosystem for charter cities. He is also the CEO of Braavos Cities, a charter city development company. With a PhD in economics from George Mason University, Mark's work focuses on innovative governance and economic development through the creation of new cities. His vision is to demonstrate better governance mechanisms and attract talent to these new urban centers.

Eli Mohamad is a serial entrepreneur and scientist, currently serving as an Entrepreneur in Residence at Narwhal Sciences, where he is incubating the Fraktus Protocol. He is a core team member of CryoDAO, focusing on advancing cryopreservation research, and has co-founded several organizations, including X-Therma and the Organ Preservation Alliance. Eli's work spans various cutting-edge fields, from tissue preservation to decentralized science, showcasing his commitment to innovation and scientific progress.

Hugo Bailly is the co-founder of Erectus DAO, a decentralized autonomous organization focused on advancing regenerative medicine and stem cell therapies. With a background in urology and extensive research experience, Hugo is dedicated to exploring innovative treatments for conditions such as erectile dysfunction and Peyronie's disease. His work aims to harness the potential of stem cells to improve patient outcomes and promote overall health.

Andrew Verbinnen is a co-founder of HairDAO, a decentralized science (DeSci) project aimed at tackling hair loss through innovative funding and research models. With a background in Government from Hamilton College and experience in private equity and cryptocurrency, Andrew transitioned to the DeSci space to address the misaligned incentives in pharmaceutical research. His work focuses on leveraging blockchain technology to democratize early-stage research and improve patient outcomes.

Mgoes is the co-founder of BiohackerDAO, a citizen science organization dedicated to data-driven self-optimization and radical human enhancement. He advocates for a minimalist, evidence-based approach to longevity, rigorously testing interventions and eliminating those that don't show clear, consistent improvements in his biomarkers. Mgoes focuses on actions that offer significant leverage, optimizing his daily routine for maximum impact. He is passionate about combining science and community collaboration to push the boundaries of human potential.

Ethan Perlstein is a visionary scientist-entrepreneur dedicated to eradicating rare diseases. As Founder/CEO of Perlara PBC, the first biotech public benefit corporation, Ethan has pioneered healthspan-extending therapeutics and cures for rare metabolic disorders. He also leads Maggie's Pearl LLC, advancing precision medicines for ultra-rare conditions, and recently launched Curetopia, a groundbreaking DAO aiming to transform rare disease treatment through decentralized collaboration. With a PhD from Harvard and impactful roles at Princeton and the Reeve Foundation, Ethan blends innovation and leadership to redefine biotech’s role in global health.

Erick Brimen is an entrepreneur and investor with extensive experience in finance and socioeconomic development. He is the founder and CEO of Próspera, a special economic zone in Honduras designed to foster economic growth and innovation. He served as CFO for Latin America at the Borealis Group, where he led the creation of multiple business units. As an entrepreneur, Erick founded ComparaMejor.com, a leading online insurance brokerage in Colombia, and NeWay Capital, focusing on alternative real estate strategies that drive socioeconomic development.

Dr. Tomer Landsberger is an entrepreneur and scientist with extensive experience in immunology and systems biology. He is the co-founder of Sciborg DAO, an organization dedicated to prolonging and enhancing human existence through the development of synthetic replacements, aiming to conquer death and enable long-term preservation of consciousness. Dr. Landsberger's scientific background includes significant contributions to the understanding of immune surveillance and senescence. Through his leadership at Sciborg DAO, Dr. Landsberger aims to integrate cutting-edge scientific research with collaborative, decentralized approaches to address the fundamental challenges of aging and mortality.

Jasmine Smith is an entrepreneur and health information specialist with a diverse background in health data management and community engagement. She is the Chief Executive Officer of Rejuve.AI, a decentralized AI-driven longevity research network committed to making healthspan extension solutions accessible and affordable to all. Under her leadership, Rejuve.AI leverages artificial intelligence and blockchain to unite individuals, clinics, researchers, and health supply vendors, fostering collaborative efforts to discover and develop interventions that promote healthy longevity. Through her work at Rejuve.AI, Ms. Smith aims to democratize access to longevity solutions, ensuring that advancements in healthspan extension benefit people worldwide.

Erik Van Winkle is an entrepreneur and operations strategist with extensive experience in decentralized science and blockchain technology. He is the Head of Operations at DeSci Labs, an organization focused on leveraging decentralized technologies to advance scientific research and innovation. Erik’s work centers on building infrastructure for open collaboration, improving research accessibility, and integrating Web3 principles into the scientific ecosystem. Through his leadership, he aims to drive the transformation of scientific funding, publishing, and data-sharing to accelerate breakthroughs in biotechnology and beyond.

Hannah Janjua is an entrepreneur and biomedical scientist focused on accelerating biotechnology through innovative decentralized platforms. She is the Co-Founder and Head of Ecosystem Development at PeptideDAO, a pioneering venture accelerating peptide research to transform health ecosystems. Hannah's scientific background includes a BSc in Biomedical Sciences from King's College London, where she showcased entrepreneurial leadership by securing a silver medal for an Alzheimer's treatment project at the prestigious iGEM competition. Her expertise bridges biomedicine, strategic partnership development, and practical innovation, aiming to unlock impactful solutions for real-world health applications.

Tim Maupin is a New York City-based director, visual effects artist, and Emmy Award-winning cinematographer with over a decade of experience in the film industry. Demonstrating a profound interest in the longevity movement, Tim directed "The Last Generation to Die," a short film set in a future where science begins to halt aging, which is currently in development as a full feature film. Furthering his dedication to the field, Tim produced the "Lifespan Docs" series for Lifespan.io, featuring short documentaries that delve into personal stories related to life extension and aging. This series aims to humanize the scientific discourse on longevity by presenting diverse perspectives. Tim is a core member and co-creator of JellyfishDAO, which seeks to fund and promote longevity-focused films, series, and media to reshape public perceptions, inspire audiences, and accelerate societal acceptance of healthy longevity through the power of storytelling. Through his multifaceted projects, Tim Maupin continues to bridge the gap between art and science, utilizing his cinematic expertise to explore and promote the possibilities of human longevity.

​Daniel Sollinger is a veteran filmmaker with a career spanning over four decades, during which he has produced an extensive portfolio of feature films, commercials, and music videos. In recent years, Daniel has channeled his storytelling expertise into the longevity movement. He co-founded JellyfishDAO, a decentralized autonomous organization uniting filmmakers, life extension experts, and blockchain innovators to create media that positively portrays life extension and healthspan technologies. His commitment to the cause is further exemplified by his role in organizing Bloom City, a pop-up village in Los Angeles set for July-August 2025. This initiative brings together longevity thought leaders, innovators, scientists, and entertainment creators to catalyze a cultural revolution prioritizing extended and enhanced human life. Daniel's dedication to merging storytelling with scientific advancement underscores his belief in the power of media to evoke emotions and inspire change within the longevity movement.

‍

Zoltan Istvan is a futurist, entrepreneur, and leading figure in the transhumanist movement, dedicated to exploring the fusion of technology and human biology to overcome natural limitations. He is the founder of the Transhumanist Party and author of "The Transhumanist Wager," a philosophical science fiction novel that has sparked extensive dialogue among futurists. Istvan's diverse career includes experience as a journalist for the National Geographic Channel, where he covered stories worldwide. His work often focuses on futurist and transhumanist themes, aiming to bring attention to the possibilities of enhancing human capabilities through technology.​ In the political arena, Istvan has been an advocate for science and technology's role in society. His diverse background and commitment to exploring the intersection of technology and human potential continue to influence discussions on the future of human enhancement and longevity.

Tim Urban is an author, speaker, and popular blogger best known for his blog, "Wait But Why." He is renowned for his engaging long-form articles and stick-figure illustrations that cover a wide range of topics, from procrastination to artificial intelligence. Tim graduated cum laude from Harvard University with a degree in Government and has co-founded several successful ventures, including ArborBridge and truePrep. His unique blend of humor and insight has earned him a large following and recognition as one of the internet's most captivating writers.

Kristen Fortney is the co-founder and CEO of BioAge Labs, a computational biology startup in Berkeley, California. She received her PhD in Medical Biophysics from the University of Toronto and completed her postdoctoral training at Stanford University. Kristen is an expert in developing bioinformatics approaches to investigate aging and age-related diseases. Her research focuses on computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity. As CEO, she leads BioAge Labs in its mission to develop therapies that target aging to increase healthspan and address chronic diseases.

Matt Kaeberlein, PhD, is the CEO of Optispan, driving innovation in predictive, preventive, and personalized healthcare. A renowned expert in aging biology, he is also a professor at the University of Washington, where he has made significant contributions to the field of oral health sciences, pathology, and genome sciences. Kaeberlein co-directs the Dog Aging Project and serves as CEO of the American Aging Association. His research on longevity and aging has earned international recognition, and he has been a leader in advancing medical solutions to extend healthy human lifespans.

Brian Kennedy is a scientist and entrepreneur, known for his significant contributions to the field of aging research. He has held leadership positions at several prominent institutions, including the Buck Institute for Research on Aging, where he served as President and CEO. Brian's work focuses on understanding the mechanisms of aging and developing interventions to promote healthy longevity. His research has been instrumental in advancing the field of biogerontology and has garnered widespread recognition.

Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.

Dr. Emil Kendziorra is the Founder and CEO of Tomorrow.Bio, a startup dedicated to advancing biostasis (cryonics) research and providing human cryopreservation services. He graduated summa cum laude from the University of Göttingen and has extensive experience in cancer research and entrepreneurship. Dr. Kendziorra has founded and led multiple tech and medical startups, including MedLanes and onFeedback. His vision is to build an organization that significantly contributes to the field of cryonics and promotes public awareness about its potential.

Andrew Steele is a scientist, writer, and campaigner based in Berlin. He holds a PhD in physics from the University of Oxford and has transitioned to computational biology, focusing on aging research. Andrew is the author of "Ageless: The New Science of Getting Older Without Getting Old" and regularly contributes to major publications like the Wall Street Journal and WIRED. He is also a popular science presenter on television and YouTube, making complex scientific concepts accessible to a broad audience.

Laurence Ion is a longevity advocate, entrepreneur, and investor dedicated to bringing aging under medical control. As the Founding Steward and Strategy Advisor at VitaDAO, he focuses on funding aging research projects and spinning out longevity biotech startups. Laurence is also the Co-initiator of Vitalia.city, a decentralized city aimed at accelerating drug development, and a Core member at JellyfishDAO, where he helps create inspiring content about longevity. His work aims to extend healthy lifespans through innovative and collaborative approaches.

Jean Hebert is a distinguished scientist and entrepreneur, currently serving as a Program Manager at ARPA-H, where he focuses on health science futures. He previously held faculty positions at the Albert Einstein College of Medicine, specializing in genetics and neuroscience. Jean is the founder of BE Therapeutics, a company dedicated to reversing age-related damage to brain tissue. His research explores stem cell transplantation, neurodegeneration, and cortical health, aiming to develop regenerative therapies for aging tissues.

Anar Isman is the co-founder and CEO of AgelessRx, a telemedicine platform dedicated to slowing down the aging process through scientifically-backed interventions. With a background in investment management, Anar transitioned to the field of longevity science driven by a desire to make a meaningful impact on human health. He believes in making cutting-edge longevity treatments accessible to everyone and is passionate about advancing the field to help people live healthier, longer lives.

Matthew "Oki" O'Connor is the Co-CEO of Cyclarity Therapeutics, a company focused on developing treatments for cardiovascular diseases through innovative cyclodextrin technology. With a Ph.D. in Biochemistry and extensive research experience in aging and regenerative medicine, O'Connor has made significant contributions to the field. His work aims to eliminate toxic oxidized cholesterol, a major factor in atherosclerosis, and improve overall healthspan.

Jun Axup is a biotechnologist and entrepreneur, currently serving as the Chief Operating Officer at E11 Bio, a non-profit focused on building high-throughput molecular tools to map the brain connectome. She previously held the position of Chief Science Officer and Partner at IndieBio, where she funded and advised over 160 companies working on improving human and planetary health. Jun holds a PhD in chemical biology from the Scripps Research Institute and has co-founded multiple startups in fields such as immuno-oncology, protein engineering, and lab automation robotics. Her passion for brain longevity and innovative biotechnological solutions drives her work.

Andrew Brack is a distinguished scientist and entrepreneur, currently serving as the Program Manager for Proactive Health at ARPA-H. He previously co-founded Arrive Bio, a biotechnology company that uses machine learning to identify drugs for age-related diseases. Andrew has a Ph.D. in molecular biology and biophysics from King’s College London and has held faculty positions at UCSF and Stanford University. His research focuses on the cellular and molecular mechanisms of skeletal muscle repair during aging.

Morten Scheibye-Knudsen is an associate professor at the University of Copenhagen, where he leads the Scheibye-Knudsen Group. His research focuses on understanding the cellular and organismal consequences of DNA damage, with the goal of developing interventions to combat age-related diseases such as Alzheimer's and Parkinson's. Morten's work has shown that replenishing certain metabolites altered by DNA damage can influence the aging process in model organisms, suggesting potential therapeutic approaches for healthier aging.

Ronjon Nag is a British-American inventor, entrepreneur, and educator, known for his pioneering work in mobile technology and artificial intelligence. He is the Founder and President of the R42 Group, a venture capital firm investing in AI and longevity companies, and an Adjunct Professor in Genetics at the Stanford School of Medicine. Ronjon has co-founded several successful companies, including Lexicus and Cellmania, and his innovations have been instrumental in advancing mobile technology. His work continues to focus on the intersection of AI and biology, aiming to create solutions for healthier aging.

Kevin Caldwell is the co-founder, President, and CEO of Ossium Health, a pioneering bioengineering company focused on creating the world's first bone marrow bank for transplants. With a background in physics and economics from MIT and a JD from Harvard Law School, Kevin has also worked as an Engagement Manager at McKinsey and a Senior Investment Associate at Bridgewater Associates. His diverse experience and dedication to improving human health through innovative solutions make him a significant figure in the biotech industry.

Mark Hamalainen is a visionary scientist and entrepreneur dedicated to extending human lifespan through innovative biotechnology. As the co-founder and co-executive director of the Longevity Biotech Fellowship, he focuses on fostering a community of researchers and innovators working on breakthrough technologies to combat aging. His career has spanned from manual bench work in academia to lab automation at Synthego, and now to building the longevity movement. Mark is passionate about finding higher leverage methods to accelerate progress in the field of longevity.

Leo Nissola, MD, is a distinguished immunologist, researcher, and cancer specialist. He serves as the Chief Scientific Officer at FirstBio Research, focusing on drug development and medical intelligence. Dr. Nissola previously worked as a Medical Oncology fellow at MD Anderson Cancer Center, supporting prostate cancer clinical trials. During the COVID-19 pandemic, he advised health officials and contributed epidemiological models used by the White House. A bestselling author of THE IMMUNITY SOLUTION, his innovative work in oncology and immunotherapy has earned international recognition, including collaborations with Nobel Laureates and industry leaders.

Alberto Aparicio is an Assistant Professor in the Department of Bioethics and Health Humanities. He completed postdoctoral fellowships at the Global Observatory for Genome Editing at Harvard University and the Alexander von Humboldt Biological Resources Research Institute in Colombia. Dr. Aparicio holds a PhD in Science and Technology Studies from University College London and an MPhil in Technology Policy from Cambridge University. With experience in policy, academia, consultancy, and government, his research focuses on the governance of emerging biotechnology and the societal implications of bioscience, including evolving attitudes toward life and technoscience.

Prof. Peter Lidsky is an expert in virology and genetics, with MS and PhD training from Moscow State University, focusing on virus-host interactions in Picornaviruses. He advanced his career at the University of Zurich, developing fluorescent imaging tools for Drosophila. At UCSF, Prof. Lidsky integrated his virology and genetics expertise, establishing a renowned research program. He is best known for developing the "pathogen control" hypothesis of aging, a pioneering framework that continues to shape his groundbreaking research on the intersection of aging, immunity, and pathogen dynamics.

Ethan Perlstein is a visionary scientist-entrepreneur dedicated to eradicating rare diseases. As Founder/CEO of Perlara PBC, the first biotech public benefit corporation, Ethan has pioneered healthspan-extending therapeutics and cures for rare metabolic disorders. He also leads Maggie's Pearl LLC, advancing precision medicines for ultra-rare conditions, and recently launched Curetopia, a groundbreaking DAO aiming to transform rare disease treatment through decentralized collaboration. With a PhD from Harvard and impactful roles at Princeton and the Reeve Foundation, Ethan blends innovation and leadership to redefine biotech’s role in global health.

Jason Kelly is an entrepreneur and innovator with over a decade of experience in synthetic biology and biotechnology. He is the co-founder and CEO of Ginkgo Bioworks, a company pioneering the use of biological engineering to create sustainable solutions across industries. Jason's background is rooted in biological engineering and computational biology, with a focus on harnessing the power of living organisms to address global challenges. His work aims to revolutionize manufacturing, agriculture, and medicine by programming biology to create a more sustainable and healthier future.

Dr Jack Scannell is best known for his work to diagnose the causes of the progressive decline in R&D productivity in the drug and biotechnology industry. He coined the term “Eroom’s Law” (from computer science’s “Moore’s Law” spelled backwards) to describe the contrast between falling biopharma R&D output efficiency since 1950 in the face of spectacular gains in basic science and in the brute force efficiency of the scientific activities on which drug discovery is generally believed to depend. His work has considered the contributions of scientific, economic, regulatory, and organisational factors. Recently, he has focused on the predictive validity of screening and disease models in drug R&D, which constitute perhaps the major productivity bottleneck. Dr Scannell is currently the CEO of Etheros Pharmaceuticals Corp. Etheros is developing small molecule enzyme mimetics, based on fullerene chemistry, for age-related and neurodegenerative diseases. He is an Associate of the Department of Science, Technology, and Innovation Studies at Edinburgh University. He led Discovery Biology at e-Therapeutics PLC, an Oxford-based biotech firm. He has experience in drug and biotech investment at UBS and at Sanford Bernstein where he ran the European Healthcare teams. He has a Ph.D. in neuroscience from Oxford University and a degree in medical sciences from Cambridge University.

Chase Denecke is an entrepreneur and scientist with extensive experience in computational biology and biotechnology. He is the founder and Chief Executive Officer of Bootstrap Bio, a company specializing in advanced biotechnological research and development. Through his leadership at Bootstrap Bio, Mr. Denecke aims to advance the development of innovative biotechnological solutions, leveraging his expertise to address complex challenges in the field.

Nathan Price is a scientist and entrepreneur with extensive experience in systems biology and biomedical research. He is the Chief Scientific Officer at Thorne and the Co-Director and Professor at the Buck Institute for Research on Aging. Nathan’s work focuses on leveraging multi-omics data, AI, and personalized health strategies to optimize human longevity and disease prevention. His research spans computational biology, precision medicine, and the development of interventions to promote healthy aging. Through his leadership in both academia and industry, he aims to transform healthcare by advancing science-driven approaches to longevity and well-being.

Xiaoxi Wei is an entrepreneur, scientist, and inventor specializing in biomimetic nanoscience and biopreservation for regenerative medicine. She is the founder and CEO of X-Therma, a pioneering company developing breakthrough ice prevention technologies to enable organ preservation and transplantation. With a vision to make "on-demand organs" a reality, Xiaoxi has dedicated her career to advancing cryopreservation and regenerative medicine. Her scientific expertise lies in supramolecular assembly and biomimetic chemistry. A recognized leader in her field, Xiaoxi has served as a healthcare advisor for the UC Regents Working Group on Innovation Transfer and Entrepreneurship, a scientific advisor to the Life Extension Foundation, and Vice Chair of the Younger Chemists Committee of the American Chemical Society. As a distinguished member of the RULEBREAKER Society in Germany, she continues to push the boundaries of science and innovation to revolutionize organ transplantation and regenerative medicine.

Jonathan Anomaly is a philosopher and academic with extensive experience in philosophy, politics, and economics programs across several prestigious universities, including Duke University, the University of North Carolina, the University of Pennsylvania, and the University of Arizona. ​He co-authored "Philosophy, Politics, and Economics," published by Oxford University Press in 2015, and authored "Creating Future People: The Ethics of Genetic Enhancement," the most recent version published by Routledge in 2024. ​His research interests include the ethics of genetic enhancement, collective action problems, and the impact of biomedical technology on society.

Léo Pio-Lopez is a scientist specializing in artificial intelligence, computational biology, and regenerative medicine. He currently serves as an Affiliate Senior Scientist at the Allen Discovery Center at Tufts University, working within Michael Levin's laboratory. His interdisciplinary research integrates AI, cognitive science, and developmental biology to uncover fundamental mechanisms of regeneration, morphogenesis, aging, and cognitive processes across multiple biological scales. With deep expertise in computational biology, deep learning, drug discovery, and bioinformatics, Léo is at the cutting edge of AI-driven approaches to understanding aging and creating targeted therapies. His work aims to harness interdisciplinary strategies to develop innovative solutions for regenerative medicine and promote healthy longevity.

We are the first generation who won’t die.

Michael Andregg builds tech to solve fundamental human challenges and expand life's flourishing across our lightcone. He founded Halcyon, which, developed high-speed, mass-producible electron microscopes and built a "molecular threader" to manipulate single DNA strands aiming at lowering the cost of DNA sequencing. He then founded Fathom, aiming at optical computing and high-bandwidth communication between chips and large memory inference for training AI at scale, now aiming at robotics. Currently, Michael leads Eon, which is developing human emulation technology for scanning people at the cell level to run high-fidelity emulations on cloud GPUs. This tech will help humanity avoid x-risks and gives solid state direct edit access to our own minds and bodies.

‍

​Sukhjit Takhar is a physician and entrepreneur with over two decades of experience in medical practice and healthcare innovation. He is the Co-Founder and Chief Medical Officer of PrimaryMD, a concierge primary care practice committed to delivering personalized and proactive healthcare services. Dr. Takhar holds board certifications in Internal Medicine, Emergency Medicine, and Infectious Disease, having completed his medical degree in 1999. He pursued residencies in Internal Medicine and Emergency Medicine, followed by a fellowship in Infectious Disease at UCLA David Geffen School of Medicine. His professional journey includes serving as an Associate Clinical Professor of Emergency Medicine at UCSF Fresno. Dr. Takhar's work focuses on integrating advanced diagnostics, preventive strategies, and lifestyle interventions to enhance patient health outcomes and longevity.

Omri Amriav-Drory is a scientist and entrepreneur, currently serving as the General Partner at NFX Bio. He is the Founder and CEO of Renewal Bio, a company focused on developing innovative solutions in the field of biotechnology. Omri previously founded Genome Compiler, which was acquired by Twist Bioscience, and has played a pivotal role in scaling and investing in influential techbio companies. His unique blend of scientific expertise and entrepreneurial experience makes him a significant figure in the techbio industry.

Anastasiya Giarletta is a prominent figure in the longevity and biotech sectors, serving as an advisor and co-founder of Aikora Health and an investor at R42 Group. Based in Silicon Valley and London, she focuses on connecting venture funds, angels, and entrepreneurs within the early-stage longevity ecosystem. Anastasiya is also a Teaching Assistant at Stanford University School of Medicine, where she lectures on Longevity Venture Capital and Healthcare Venture Capital. Her extensive network and expertise make her a key influencer in advancing healthcare and human aging technologies.

Phil Newman is the Founder and CEO of Longevity.Technology, a leading media and investment platform focused on the longevity megatrend. He has held multiple C-level management positions, applying his marketing and business development expertise in sectors such as longevity, IoT, bionics, medical devices, biopharma, and 3D manufacturing. Phil's work aims to bring together innovators and investors to commercialize companies that will form the longevity economy.

Dr. Emil Kendziorra is the Founder and CEO of Tomorrow.Bio, a startup dedicated to advancing biostasis (cryonics) research and providing human cryopreservation services. He graduated summa cum laude from the University of Göttingen and has extensive experience in cancer research and entrepreneurship. Dr. Kendziorra has founded and led multiple tech and medical startups, including MedLanes and onFeedback. His vision is to build an organization that significantly contributes to the field of cryonics and promotes public awareness about its potential.

Nils Regge is a serial entrepreneur and investor with a strong passion for health and biotechnology. He is the co-founder and Managing Director of Apollo Health Ventures, a venture capital fund focused on aging and age-related diseases. Nils has founded several successful companies, including TruVenturo and HomeToGo, and has been involved in numerous financing rounds. His expertise in growing early-stage startups and his commitment to advancing biomedicine make him a key player in the longevity sector.

Karl Pfleger is a prominent angel investor and advocate for longevity research, known for his significant contributions to the biotech industry. He is an investor in Repair Biotechnologies, focusing on gene therapy for age-related diseases, and runs Aging Biotech Info, a valuable resource for the longevity community. Karl's background in machine learning and his dedication to supporting groundbreaking research make him a key figure in the fight against aging.

Ole Mensching, Ph.D., is the co-founder and General Partner of Apollo Ventures, a venture capital fund dedicated to aging and age-related diseases. He has a strong background in investment and operations, previously co-founding CareerTeam, a successful headhunting agency. Ole holds a Ph.D. from the University of California, Berkeley, and the University of Cologne, and his expertise in HR and team building has been instrumental in supporting Apollo's portfolio companies.

Sebastian Brunemeier is a biotech venture capitalist and company builder focused on longevity and regenerative medicine. He is the co-founder and General Partner of Healthspan Capital and the CEO and founder of ImmuneAGE Bio, a company dedicated to immune system rejuvenation. Sebastian has co-founded several longevity biotech companies, contributing to significant advancements in the field. His extensive experience and dedication to improving human healthspan have made him a respected figure in the biotech industry.

David Gobel is a philanthropist, entrepreneur, inventor, and futurist, best known for co-founding the Methuselah Foundation, which focuses on extending healthy human lifespans through regenerative medicine and biotechnology. He has been a driving force in promoting the concept of longevity escape velocity and has supported numerous projects and companies aimed at combating age-related diseases. David's visionary work continues to inspire advancements in the field of life extension.

Anar Isman is the co-founder and CEO of AgelessRx, a telemedicine platform dedicated to slowing down the aging process through scientifically-backed interventions. With a background in investment management, Anar transitioned to the field of longevity science driven by a desire to make a meaningful impact on human health. He believes in making cutting-edge longevity treatments accessible to everyone and is passionate about advancing the field to help people live healthier, longer lives.

Aykut Karaalioglu is an accomplished entrepreneur and investor, best known for founding MobileAction, a company specializing in app discovery and optimization. He has held various leadership roles, including CEO of SearchAds.comand Growth Lead at ScoreBeyond. Aykut is also an active angel investor and advisor to several startups, leveraging his extensive experience in product management and user acquisition to drive innovation and growth in the tech industry.

Matthew "Oki" O'Connor is the Co-CEO of Cyclarity Therapeutics, a company focused on developing treatments for cardiovascular diseases through innovative cyclodextrin technology. With a Ph.D. in Biochemistry and extensive research experience in aging and regenerative medicine, O'Connor has made significant contributions to the field. His work aims to eliminate toxic oxidized cholesterol, a major factor in atherosclerosis, and improve overall healthspan.

Mac Davis is the founder of Minicircle, a pioneering company focused on revolutionizing gene therapy. With a mission to enhance human health and sovereignty, he developed a reversible human genetic enhancement protocol that uses non-inflammatory, non-heritable plasmids to safely introduce genes into the body without altering the genome. Mac’s innovative approach challenges traditional medical practices, offering a fast, accessible, and ethical alternative to lifelong treatments. His work aims to empower individuals and communities, ensuring that gene therapy is available to all, free from the constraints of the current healthcare system.

Parmita Mishra is a computational biologist and entrepreneur, known for founding Precigenetics, a company focused on developing advanced non-invasive diagnostic tools that integrate biophotonics with machine learning. She is dedicated to pushing the boundaries of healthcare technology, particularly in the field of non-invasive cancer diagnostics. Parmita's work aims to enhance the identification of molecular signatures unique to cancerous cells, leveraging machine learning algorithms to improve detection and classification.

Kevin Caldwell is the co-founder, President, and CEO of Ossium Health, a pioneering bioengineering company focused on creating the world's first bone marrow bank for transplants. With a background in physics and economics from MIT and a JD from Harvard Law School, Kevin has also worked as an Engagement Manager at McKinsey and a Senior Investment Associate at Bridgewater Associates. His diverse experience and dedication to improving human health through innovative solutions make him a significant figure in the biotech industry.

Petr Sramek is a visionary entrepreneur and investor dedicated to advancing human health and longevity. As the co-founder, chairman, and managing partner of Longevitytech.fund, he focuses on supporting innovative startups that aim to extend healthy lifespans. Petr is also the founder and CEO of HealthyLongevity.clinic and HealthyLongevity.cafe, where he works on personalized health strategies and longevity solutions. With a background in engineering and extensive experience in the tech industry, Petr is committed to building the infrastructure needed to accelerate the adoption of health-span improving technologies.

Nish Bhat is an entrepreneur and investor with extensive experience in biotechnology and venture capital. He is the Founder and General Partner of Carbon Silicon Ventures, a firm dedicated to supporting startups that integrate engineering principles with biological sciences to drive innovation in healthcare. Before establishing Carbon Silicon Ventures, Mr. Bhat co-founded Color Health, Inc. in 2013, a company specializing in genetic testing services for various hereditary cancers. He also co-founded SciFounders, a venture capital firm launched in 2021, and serves on the board of Reference Medicine, a company focused on making specimens more affordable and accessible for oncology diagnostic developers. His journey reflects a commitment to advancing the intersection of biology and engineering, aiming to transform healthcare through innovative solutions.

‍

Dr. Dave Messina is an entrepreneur and scientist with over 25 years of experience in computational biology and human genetics. He serves as General Partner at Pioneer Fund and leads the Future of Health Fund. Prior to joining Pioneer Fund, Dr. Messina co-founded Cofactor Genomics, a company specializing in RNA and machine-learning-based diagnostics, where he led the development and clinical application of innovative diagnostic tools. Through his leadership at Pioneer Fund, he aims to advance the development of innovative health and biotechnology solutions, leveraging his extensive experience to support groundbreaking startups in the industry.

Boyang Wang is an entrepreneur and investor with a strong background in computer science and a passion for the gaming and longevity industries. He is the founder of Immortal Dragons, a purpose-driven longevity fund dedicated to advancing research and innovation in life extension technologies. In addition to his entrepreneurial ventures, Boyang actively contributes to the longevity community. He serves as a senior venture fellow at Healthspan Capital, one of the most active longevity-focused venture capital funds. His engagement extends to speaking at conferences and participating in podcasts, where he shares insights on the convergence of technology, gaming, and life extension. Through his diverse endeavors, Boyang Wang continues to influence both the gaming industry and the field of longevity, driving forward initiatives that blend technological advancement with human health and well-being.

Joe Betts-LaCroix is an American scientist and entrepreneur known for his discoveries in biophysics and for creating the world's smallest personal computer. He is currently the co-founder and CEO of Retro Biosciences, a company focused on developing therapeutics to increase healthy human lifespan by ten years. Joe has a background in earth sciences, biophysics, and computer hardware, and has contributed to significant advancements in both scientific research and technology innovation.

Derya Unutmaz, MD, is a distinguished professor at The Jackson Laboratory, renowned for his pioneering work on human T cell differentiation, activation, and regulation in immunity, diseases, and aging. With a medical degree from Marmara University, Istanbul, he also holds a concurrent professorship at the University of Connecticut Health Center. Dr. Unutmaz’s research has transformed understanding of T cell dysfunction in diseases like HIV and chronic fatigue syndrome. His work aims to optimize immune responses and develop therapies that combat age-related diseases, advancing healthier aging and immune system treatments.

​Sonia Arrison is a best-selling author, analyst, entrepreneur, and investor with over two decades of experience studying the impact of new technologies on society. She is the founder of 100 Plus Capital, Lead Venture Partner at Portfolia, and serves as an advisor to Felicis Ventures, organizations that invest at the convergence of biology and technology. Sonia focuses her efforts on exponentially growing technologies and their societal implications. Her most recent book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity. Through her diverse endeavors, Sonia Arrison continues to influence the discourse on technology's role in shaping the future, particularly in the realms of human longevity and societal transformation.

Allison Duettmann is the President and CEO of the Foresight Institute, where she directs programs on Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs. She is also the Founder of Existential Hope and has co-edited works on superintelligence and co-authored books on future technologies. Allison holds an MS in Philosophy & Public Policy from the London School of Economics, focusing on AI Safety. She is a prominent advocate for leveraging technology to create a positive long-term future for humanity.

John Cumbers is a British molecular biologist and entrepreneur based in the San Francisco Bay Area. He is the founder and CEO of SynBioBeta, an organization that promotes synthetic biology to build a more sustainable universe. John also founded BetaSpace, a space settlement innovation network, and is an operating partner at DCVC, a venture capital firm focused on biotechnology investments. His work at NASA and his contributions to synthetic biology have earned him multiple awards and recognition in the field.

Alexandrul-Ioan Voda, DPhil, is a passionate leader in regenerative medicine, bioinformatics, and biotech. As CEO of The Cat Health Company, Alex leverages a diverse skill set combining wet-lab and computational sciences to drive advancements in biomedical research. A coding aficionado fluent in Python, R, and Bash, Alex specializes in machine learning, data structures, and algorithms. With a DPhil from the University of Oxford, he has contributed to groundbreaking work in inflammatory bowel disease genetics, aging clocks, and human health. His experience spans both academic and industry sectors, with a strong focus on innovation and scientific leadership.

Alexandru Băcița is a scientist and entrepreneur with extensive experience in drug discovery and development. He is the co-founder and Chief Operating Officer of The Cat Health Company (TCHC), a biotech startup dedicated to extending feline longevity through innovative therapies. Before co-founding TCHC, Alexandru served as a Senior Scientist at Charles River Laboratories, a leading provider of services for drug discovery and clinical trials. At TCHC, Alexandru focuses on developing computational pipelines to predict new therapies for rare diseases and age-related conditions in cats. His work aims to enhance feline health and longevity, providing pets with longer, healthier lives

Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.

Dr. Morgan Levine is a prominent scientist specializing in the biology of aging, with extensive experience in academic research and computational biology. She currently serves as the Vice President of Computation at Altos Labs, a biotechnology company focused on restoring cell health and resilience through cell rejuvenation. Dr. Levine's scientific background encompasses bioinformatics, cellular biology, complex systems, and biostatistics. She is renowned for developing innovative methods to quantify the molecular and physiological changes that occur over an organism's lifetime, integrating interdisciplinary approaches to track the trajectories of aging cells and organisms. Her vision includes creating multi-scale computational models to elucidate how dynamic molecular states of cells lead to health and disease manifestations at various biological levels. Her work aims to uncover the principles of aging and develop interventions to promote healthy longevity.

Dr. Sam Rodriques is a physicist, bioengineer, and entrepreneur with extensive experience in academic research and biotechnology innovation. He is the founder and CEO of FutureHouse, a research lab in San Francisco dedicated to developing an AI Scientist to accelerate scientific discovery. Before establishing FutureHouse in 2023, Dr. Rodriques led the Applied Biotechnology Laboratory at the Francis Crick Institute, where he focused on integrating bioengineering and business to advance medical and biological research. His notable inventions include technologies for spatial and temporal transcriptomics, brain mapping, gene therapy, and nanofabrication. Throughout his career, Dr. Rodriques has been committed to accelerating scientific research through innovative technologies and interdisciplinary approaches. His work aims to revolutionize the pace of discovery and provide global access to cutting-edge scientific, medical, and engineering expertise.

Dr. Zihao Ou is an Assistant Professor in the Biomedical Science Program and the Department of Physics at the University of Texas at Dallas. Dr. Ou’s research focus lies at the intersection of fundamental physical principles and cutting-edge genetic and molecular advancements. His goal is to create advanced imaging platforms that allow real-time monitoring of materials and biological processes in their native environments.

Mariëlle is a scientist, engineer and entrepreneur who aims to develop transformative technology that will accelerate progress in the longevity community, move the frontiers of synthetic biology, and shape commercial initiatives that target mitochondrial disease and dysfunction. As a Postdoctoral Research Fellow at Stanford University, Mariëlle set out to deduce and employ gene regulatory networks in human cells at RNA isoform resolution to improve human health.

Tom Kalil is CEO of Renaissance Philanthropy, Chair of Convergent Research, and a Board Member of Future House.  He previously served as Chief Innovation Officer at Schmidt Futures, where he recommended funding for hundreds of science and technology-related projects.  He also helped design and launch dozens of science and technology initiatives for Presidents Obama and Clinton in fields such as nanotechnology, materials by design, neuroscience, data science, robotics, educational technology, access to capital, high-skill immigration, and incentive prizes.

Erika is a former astronomer and current synthetic biologist.  In 2021 she founded The Align Foundation, a nonprofit improving the reproducibility, scalability, and shareability of life science research. Align aims to make it easy to build upon the methods and data of other scientists, allowing scientific fields to accumulate data assets to train AI models.

Alfredo Andere is the co-founder and CEO of LatchBio, a platform that provides biology companies with the tools to store, transform, and analyze large data sets. Before founding LatchBio, he worked as a Data Engineer at Facebook and a Software Engineer at Google Brain, gaining valuable experience in handling large-scale data. Alfredo and his co-founders envisioned bringing high-quality computational infrastructure to the field of biology, and they dropped out of their senior year at UC Berkeley to pursue this goal. Since its inception, LatchBio has raised significant funding and serves numerous biotech companies.

Max More is a philosopher and futurist known for his work on transhumanism and the philosophy of extropy. He is the founder of the Extropy Institute and has served as President and CEO of the Alcor Life Extension Foundation. Max holds a degree in Philosophy, Politics, and Economics from Oxford University and a PhD in Philosophy from the University of Southern California. His writings and ideas have significantly influenced the transhumanist movement, focusing on the potential of emerging technologies to enhance human capabilities and extend life.

Ralf Spindler is a leading scientist and innovator with extensive expertise in neural systems cryopreservation. As the Head of Neural Systems Cryopreservation at 21st Century Medicine, he plays a pivotal role in advancing preservation techniques critical to the field of cryobiology. With a background in electrical and biomedical engineering, Ralf's research focuses on improving methods to preserve the human brain and other neural structures at ultra-low temperatures, with the goal of ensuring their integrity for future revival. His work is at the forefront of bridging the gap between cutting-edge science and long-term human preservation.

Dr. Emil Kendziorra is the Founder and CEO of Tomorrow.Bio, a startup dedicated to advancing biostasis (cryonics) research and providing human cryopreservation services. He graduated summa cum laude from the University of Göttingen and has extensive experience in cancer research and entrepreneurship. Dr. Kendziorra has founded and led multiple tech and medical startups, including MedLanes and onFeedback. His vision is to build an organization that significantly contributes to the field of cryonics and promotes public awareness about its potential.

Ariel Zeleznikow-Johnston is a neuroscientist at Monash University, Australia, where he investigates methods for characterising the nature of conscious experiences. Ariel is also the author of "The Future Loves You: How and Why We Should Abolish Death", and has been featured in major publications like The Guardian and the BBC. His research interests range from the decline, preservation and rescue of cognitive function at different stages of the lifespan, through to comparing different people’s conscious experience of colour. By contributing to research that clarifies the neurobiological, cognitive, and philosophical basis of what it is to be a person, he hopes to accelerate the development of medical infrastructure that will help prevent him and everyone else from dying.

Sebastian Giwa is an entrepreneur and innovator with extensive experience in biotechnology and translational research. He is the founder of Sylvatica Biotech, a company at the forefront of developing advanced preservation technologies to enable organ banking and improve global access to transplantation. Sebastian's background spans cryobiology, tissue engineering, and regenerative medicine, with a focus on overcoming the challenges of long-term organ storage. His work aims to revolutionize healthcare by creating solutions that enhance the availability and efficiency of life-saving organ transplants worldwide.

Throughout his career, Andrew McKenzie has contributed to the understanding of brain cell type-specific gene expression and co-expression network architectures. His work aims to advance the field of neuroscience through innovative research and collaboration. Dr. McKenzie's research focuses on brain banking, ischemic alterations in the brain, and long-term preservation methods. His scholarly work emphasizes structural brain preservation, guiding the research directions at Oregon Brain Preservation, a non-profit organization.

Kai Micah Mills is the CEO of Cryopets, a startup specializing in cryopreservation for pets, and a co-founder of CryoDAO, a decentralized organization funding cryonics research. With a background as a tech entrepreneur and Thiel Fellow, Kai is dedicated to advancing cryopreservation technologies and making significant contributions to the field of life extension.

James Arrowood is an entrepreneur, legal expert, and executive with extensive experience in the life extension and biotechnology sectors. He is the Co-CEO of the Alcor Life Extension Foundation, where he has been instrumental in guiding the organization since 2015. James initially joined Alcor as outside General Counsel, helping navigate complex legal and business challenges. He has also served on the board of directors for a major local non-profit and as its public relations chair, contributing to his long-standing expertise in media and public relations. His work focuses on advancing Alcor’s mission and engaging with the wider conversation on cutting-edge technologies aimed at extending human lifespan.

Ralph C. Merkle is a computer scientist and cryptographer with over 40 years of experience in academic research and technological innovation. He is a board member at the Alcor Life Extension Foundation, an organization focused on cryonics and life extension. Ralph's scientific background encompasses public key cryptography, cryptographic hashing, and nanotechnology. His work aims to advance secure communication systems and explore technologies to extend human life.

Aschwin de Wolf is a Dutch-born American cryobiologist and entrepreneur with extensive experience in cryonics research and writing. He is the co-founder and Chief Executive Officer of Advanced Neural Biosciences (ANB), a biomedical research company established in 2008. ANB focuses on developing low-temperature technologies to preserve central nervous tissue and whole brains, aiming to advance brain banking, pharmacological drug discovery, and the study of neurodegenerative diseases. He co-authored the first comprehensive human cryopreservation procedures manual and authored the first medical biostasis protocol. Aschwin's involvement in cryonics extends to founding the Depressed Metabolism blog in 2007, which later evolved into Biostasis.com. He also co-founded and served as president of the Institute for Evidence-Based Cryonics. Through his work, Aschwin aims to advance the science and application of cryopreservation techniques, contributing to the potential for future medical applications and the extension of human life.

Brian G. Wowk is a medical physicist and cryobiologist with over 20 years of experience in cryobiological research and technology development. He serves as the Chief Technology Officer at 21st Century Medicine, where he has been instrumental in advancing cryopreservation techniques. In his role at 21st Century Medicine, Dr. Wowk continues to lead efforts in developing advanced cryobiological technologies, aiming to improve the preservation and longevity of biological tissues and organs. Dr. Wowk's notable contributions include the discovery and development of synthetic molecules that mimic natural antifreeze proteins, commonly referred to as "ice blockers." These innovations have been pivotal in enabling the vitrification and successful transplantation of complex mammalian organs, such as kidneys. He is presently refining electromagnetic warming methods for vitrified whole organs.

Rebecca Ziegler is a cryonics specialist with a focus on advancing human cryopreservation technologies. She helped organize the 2024 Global Cryonics Summit, which brought together cryonics experts to develop a cohesive cryonics community and spark new ideas. She served as a Product Manager at Tomorrow Bio, a company dedicated to making cryonics more accessible and reliable through state-of-the-art preservation techniques and emergency standby services. Now she serves as a Director at the Cryosphere Foundation, with the goal to bring together experts and foster a cohesive cryonics community. Her work aims to refine cryonics processes and make human cryopreservation more accessible and effective.

‍

Eric Magro is an entrepreneur and advocate for life extension, dedicated to advancing the fields of cryonics and longevity policy. He is the Co-Founder of Cryosphere, a platform focused on fostering community and innovation in cryonics. As Director of Operations at LongeviPAC, Eric works to shape policies that support life extension technologies and research. He helped organize the 2024 Global Cryonics Summit, which brought together experts to provide the space and resources to push projects forward. His efforts bring together scientific progress and public policy, ensuring that advancements in longevity science receive the attention and support they deserve. Through his work, Eric aims to accelerate the development of life-preserving technologies and expand access to cutting-edge longevity solutions.

‍

Max Marty is a serial entrepreneur and active member of the cryonics community. In 2011, Max co-founded Blueseed, a project aimed at creating a floating startup incubator off the coast of California. The initiative sought to provide a visa-free environment for international entrepreneurs to collaborate and innovate near Silicon Valley. He is the creator of The Cryosphere, an online cryonics-focused community, fostering discussions among enthusiasts and professionals. He helped organize the 2024 Global Cryonics Summit, which connected experts from the industry and community. Max also co-hosts The Cryosphere Podcast, where he engages with key figures in the field to explore the scientific, social, and philosophical aspects of cryonics. Through his initiatives, Max aims to advance public understanding and acceptance of cryonics as a viable option for life extension. Max's diverse entrepreneurial ventures reflect his commitment to pioneering unconventional solutions and fostering global collaboration in technology and life extension.

‍

Dr. Nick Llewellyn is a biomedical researcher with over 20 years of experience in molecular and cellular biology. In November 2024, Dr. Llewellyn joined the Alcor Life Extension Foundation as Director of Research and Development, where he leads efforts to advance cryopreservation techniques and organ viability assessments. Under his direction, Alcor has established a dedicated laboratory space and assembled a team of specialists from top institutions to tackle preservation challenges. Dr. Llewellyn's current projects include the cryopreservation and normothermic perfusion of pig kidneys, aiming to test organ viability before and after cryopreservation.

Daniel Walters is a prominent advocate for cryonics and life extension, with extensive experience in community engagement and digital outreach. He is the co-host of the Cryosphere Podcast, where he explores the latest advancements, challenges, and philosophies surrounding cryopreservation. He helped organize the 2024 Global Cryonics Summit, which brought together experts to foster a cohesive cryonics community. With deep roots in the cryonics community, Daniel has played a key role in fostering discussion and awareness. As Community Outreach Coordinator at Alcor Life Extension Foundation, Daniel is focused on transforming Alcor’s digital presence by enhancing member communications, expanding social media engagement, and modernizing its online platforms. His work bridges the gap between scientific progress and public awareness, ensuring that cryonics continues to gain traction as a viable approach to life extension.

Robin Hanson is an associate professor of economics at George Mason University and a research associate at the Future of Humanity Institute at Oxford University. He is known for his pioneering work on prediction markets, also known as idea futures, and has been a key figure in developing these markets for various applications. Robin has authored several influential books, including "The Age of Em: Work, Love and Life When Robots Rule the Earth" and "The Elephant in the Brain: Hidden Motives in Everyday Life." His research spans a wide range of topics, from spatial product competition to the bioethics of healthcare, and he is a prominent advocate for futarchy, a form of governance based on prediction markets.

Jason Sorens is an American political scientist and conservative libertarian activist, best known for founding the Free State Project in 2001. He holds a PhD in political science from Yale University and a BA in economics and philosophy from Washington and Lee University. Jason has taught at several prestigious institutions, including Yale, Dartmouth, and the University at Buffalo. His research focuses on fiscal federalism, public policy in federal systems, secessionism, and ethnic politics. He is also a Senior Research Fellow at the American Institute for Economic Research (AIER) and president of the Ethics and Economics Education of New England (E3NE).

Breanna Deutsch is a policy expert and author, known for her work in political communications and advocacy for life extension technologies. She is the Secretary of the Board at A4LI and the author of "Finding the Fountain: Why Government Must Unlock Biotech's Potential to Maximize Longevity." Breanna's efforts focus on encouraging policymakers to support aging research and promote healthier lifespans through government initiatives.

Arkadi Mazin is a seasoned journalist and op-ed author with a passion for learning and exploration. His interests span from politics to science and philosophy. Having studied economics and international relations, he is particularly interested in the social aspects of longevity and life extension. Arkadi is dedicated to promoting the idea that life extension is an achievable and noble goal that deserves greater attention and action from society.

Alberto Aparicio is an Assistant Professor in the Department of Bioethics and Health Humanities. He completed postdoctoral fellowships at the Global Observatory for Genome Editing at Harvard University and the Alexander von Humboldt Biological Resources Research Institute in Colombia. Dr. Aparicio holds a PhD in Science and Technology Studies from University College London and an MPhil in Technology Policy from Cambridge University. With experience in policy, academia, consultancy, and government, his research focuses on the governance of emerging biotechnology and the societal implications of bioscience, including evolving attitudes toward life and technoscience.

Kamen Shoylev is a dual-qualified lawyer, practicing at both the Bulgarian and English Bars. As co-managing partner at New Balkans Law Office, he provides expert advice on corporate, commercial, regulatory, and IP law, focusing on cross-border issues between Bulgaria, the EU, and the UK. Kamen’s legal expertise spans corporate disputes, EU law, and intellectual property. With a keen interest in innovation and longevity, he integrates his knowledge of science, technology, and investment ethics into his work. Kamen holds a B.A. in Law from Cambridge University and is committed to advancing entrepreneurial and legal solutions globally.

Dr. Hisham Badaruddin is a medical doctor and public health specialist with over 25 years of experience in the healthcare system. He is the founder and CEO of Bartley Clinic, a general practice in Singapore that integrates primary care with longevity medicine to make advanced healthcare more accessible. At Bartley Clinic, Dr. Hisham focuses on preventive medicine, health screening, lifestyle medicine, and modern longevity science, aiming to optimize health and extend disease-free years for his patients. Throughout his career, Dr. Hisham has held leadership roles in biopharma, healthcare insurance, and telehealth companies.

Dylan Livingston is the Founder and President of the Alliance for Longevity Initiatives (A4LI), a non-profit organization focused on advocating for policies that promote healthy human lifespan. He has a background in grassroots political organizing and has worked with various political campaigns, including the Biden campaign in Pennsylvania. Dylan is passionate about increasing equitable access to next-generation therapies and has been involved in the longevity community since childhood, influenced by his father's early-stage investments in futuristic technologies.

John Davis is a philosopher and author, best known for his work "New Methuselahs: The Ethics of Life Extension." In this book, Davis explores the ethical implications of extending human life, addressing issues such as desirability, unequal access, and potential overpopulation. His philosophical discussions provide a comprehensive guide to the ethical considerations of life extension, making a compelling case for funding research in this field.

Patrick Linden is a philosopher and author, known for his work on the ethics of life extension and the philosophy of death. He has taught at various prestigious institutions, including Lund University, UCL, and NYU. His book, "The Case Against Death," argues that death is an evil that should be combated through anti-aging science and radical life extension. Linden's work challenges traditional views on mortality and advocates for a future where humans can live significantly longer, healthier lives.

Gennady Stolyarov II is a Belarusian-American libertarian and transhumanist writer, actuary, and civil servant. He is best known for his book "Death is Wrong," which argues that death is an enemy to be overcome through technology. Gennady is also the Chairman of the Transhumanist Party, advocating for life extension and the use of science and technology to enhance human capabilities.

Felix Werth is a biochemist and political advocate, best known for founding the Party for Rejuvenation Research in Germany. The party focuses on accelerating the development of regenerative medicine to extend healthy human lifespans. As the party's leader, Felix is dedicated to raising public awareness and support for rejuvenation research, aiming to prevent age-related diseases and promote longer, healthier lives.

John Martin Fischer is a Distinguished Professor of Philosophy at the University of California, Riverside, and a leading contributor to the philosophy of free will and moral responsibility. He is known for his theory of semi-compatibilism, which explores the relationship between free will and moral responsibility. Fischer has also made significant contributions to the metaphysics of death and the philosophy of religion. He has served as President of the American Philosophical Association, Pacific Division, and was elected a Fellow of the American Academy of Arts and Sciences in 2024.

Melissa King is a strategic management and communications executive with extensive experience in global healthcare and research policy. She is the Chief Operating Officer and a Founding Board Member of the Healthspan Action Coalition, an organization dedicated to promoting healthy aging and advancing medical research to reduce the burden of chronic diseases. Throughout her career, Melissa has been a passionate advocate for patients suffering from chronic illnesses, focusing on accelerating medical advancements and ensuring equitable access to innovative treatments. She has played a pivotal role in engaging multiple stakeholders and effectively communicating complex scientific concepts to diverse audiences.

Niklas Anzinger is an entrepreneur and investor with a focus on innovative urban development and regulatory frameworks. He is the founder and CEO of Infinita City, an organization dedicated to leveraging special regulatory zones to accelerate biomedical progress. Niklas is also the founder and general partner of Infinita VC, a venture capital firm based in the charter city of Próspera in Honduras, focusing on charter cities and alternative jurisdictions. His work creates scalable regulatory solutions that can be applied across multiple jurisdictions, fostering environments conducive to innovation and progress.

Dr. Chris Wareham is an assistant professor at the Ethics Institute of Utrecht University, specializing in applied ethics and bioethics. His research focuses on the ethical implications of aging and life extension, as well as emerging biotechnologies, often examined through the lens of African ethical systems. In this area of research, he edited The Cambridge Handbook of the Ethics of Ageing, which approaches the implications of aging for individual well-being, social policy, and social justice. In addition, he works on emerging biotechnologies and his published work often examines these through the lens of African ethical systems. His work aims to address ethical challenges related to aging, life extension, and biotechnology, with a particular interest in how these issues intersect with concepts of personhood and moral status in African philosophy.

Andrés Gómez Emilsson is a consciousness researcher and transdisciplinary scientist exploring the nature of subjective experience. He is the Director of Research at the Qualia Research Institute, an organization dedicated to developing a precise scientific understanding of qualia and its implications for well-being. His work integrates insights from neuroscience, computational modeling, and philosophy to advance the study of consciousness. Andrés is particularly interested in the structure of phenomenology, the neurotechnology of altered states, and the ethical implications of enhancing subjective experience. Through his research, he aims to uncover fundamental principles of consciousness and develop frameworks for its rigorous quantification and optimization.

Eric Magro is an entrepreneur and advocate for life extension, dedicated to advancing the fields of cryonics and longevity policy. He is the Co-Founder of Cryosphere, a platform focused on fostering community and innovation in cryonics. As Director of Operations at LongeviPAC, Eric works to shape policies that support life extension technologies and research. He helped organize the 2024 Global Cryonics Summit, which brought together experts to provide the space and resources to push projects forward. His efforts bring together scientific progress and public policy, ensuring that advancements in longevity science receive the attention and support they deserve. Through his work, Eric aims to accelerate the development of life-preserving technologies and expand access to cutting-edge longevity solutions.

‍

​Nico Arcino is a seasoned technology leader with extensive experience in both dynamic startups and large foundational institutions. He currently serves as the Chief Technology Officer at Primasun, a company dedicated to advancing sleep health through innovative technological solutions. Prior to joining Primasun, Nico held the position of Senior Director of Strategic Partnerships at Kaiser Permanente, where he played a pivotal role in forging collaborations that enhanced healthcare delivery and technological integration. Throughout his career, Nico has been recognized as a health and tech innovator, consistently contributing to advancements at the intersection of healthcare and technology. His diverse background and strategic insights continue to drive Primasun's mission to revolutionize sleep health.